Pages that link to "Q35855167"
Jump to navigation
Jump to search
The following pages link to Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia (Q35855167):
Displaying 50 items.
- Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia (Q21260279) (← links)
- An approach to maximizing treatment adherence of children and adolescents with psychotic disorders and major mood disorders (Q24644760) (← links)
- Urgent Psychiatric Services: A Scoping Review (Q26784574) (← links)
- Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia (Q28545127) (← links)
- The Post-Discharge Network Coordination Programme: A Randomized Controlled Trial to Evaluate the Efficacy of an Intervention Aimed at Reducing Rehospitalizations and Improving Mental Health. (Q30385527) (← links)
- Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds. (Q30571895) (← links)
- Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data (Q31049583) (← links)
- Survey of medication adherence in patients with schizophrenia--Korean ADHES data (Q31081061) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia (Q33235110) (← links)
- What is the best approach to treating schizophrenia in developing countries? (Q33288244) (← links)
- Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia (Q33399275) (← links)
- A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss (Q33410397) (← links)
- Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients (Q33488323) (← links)
- The cost of relapse and the predictors of relapse in the treatment of schizophrenia (Q33522776) (← links)
- Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies (Q33536043) (← links)
- Noncompliance in the use of cardiovascular medications in the Medicare Part D population (Q33567812) (← links)
- Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review (Q33589087) (← links)
- Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. (Q33633758) (← links)
- The frequency of rehospitalization and associated factors in Colombian psychiatric patients: a cohort study (Q33763632) (← links)
- Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study (Q33797431) (← links)
- Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection (Q33817737) (← links)
- Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death (Q33848968) (← links)
- Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies (Q33857710) (← links)
- Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium (Q33862078) (← links)
- Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database (Q33932365) (← links)
- Implementing performance improvement and measuring psychiatric care quality (Q34064599) (← links)
- Changes in Guideline-Recommended Medication Possession After Implementing Kendra's Law in New York (Q34141364) (← links)
- Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence (Q34144373) (← links)
- Patient perspectives on antipsychotic treatments and their association with clinical outcomes (Q34231565) (← links)
- Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data (Q34286350) (← links)
- Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study (Q34293899) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (Q34315836) (← links)
- Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study (Q34318836) (← links)
- Self-disorders and schizophrenia: a phenomenological reappraisal of poor insight and noncompliance (Q34353395) (← links)
- Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study (Q34362623) (← links)
- Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study (Q34374891) (← links)
- A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia (Q34444162) (← links)
- Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia (Q34486175) (← links)
- Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses (Q34588656) (← links)
- Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders (Q34650576) (← links)
- Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. (Q34680925) (← links)
- Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review (Q34775426) (← links)
- Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization (Q35008229) (← links)
- Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence (Q35018988) (← links)
- Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness (Q35065381) (← links)
- Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness (Q35073474) (← links)
- Subjective and Objective Cognitive Dysfunction in Schizophrenia – is there a Link? (Q35091697) (← links)
- Clinical potential of lurasidone in the management of schizophrenia (Q35093143) (← links)
- Deltoid injections of risperidone long-acting injectable in patients with schizophrenia (Q35119881) (← links)
- Predictors of frequent recourse to health professionals by people with severe mental disorders (Q35132686) (← links)